Department of Internal Medicine, Atlantic Health System, USAFulltext PDF
Evan’s syndrome is a rare entity which presents with autoimmune hemolytic anemia and immune thrombocytopenia in the absence of an underlying etiology. In this particular case, the patient initially presented with hemolytic anemia and developed thrombocytopenia later in the hospital course. There was no evidence of autoimmune conditions or malignancies. The patient failed to respond to steroids and intravenous immunoglobulin, therefore he was subsequently treated with Rituximab. Hemoglobin and platelet count stabilized and the patient has been off treatment since then.
Immune thrombocytopenia; Intravenous immunoglobulin; Lactate dehydrogenase
Holguin S. Evan’s Syndrome Successfully Treated with Rituximab. J Hematol Mult Myeloma. 2019;4(1):1020.